503B outsourcing facility

A pharmacy designation for compounded medications prepared in larger batches with stricter regulatory oversight. Also cannot compound BPC-157. On ProcedureFinder, 503B outsourcing facility appears in the BPC-157 Peptide Therapy, Semaglutide for Weight Loss, Tirzepatide for Weight Loss cost guides. BPC-157 has been studied in over 100 published animal model papers, primarily from a single research group at the University of Zagreb.

BPC-157 Peptide Therapy costs $250 to $1,200 per month (when available); historical pricing 2022-2023 era nationally, with a median of $450 in ProcedureFinder's cash-pay benchmarks. A 15-amino-acid pentadecapeptide derived from a gastric protein, marketed for tendon, ligament, and gut healing. Currently restricted by FDA from 503A compounding.

Semaglutide for Weight Loss costs $199 to $1,400 per month all-inclusive (medication + provider + supplies) nationally, with a median of $350 in ProcedureFinder's cash-pay benchmarks. Weekly GLP-1 receptor agonist injection that reduces appetite and food cravings, typically producing 12 to 17 percent body weight loss over 12 months.

Tirzepatide for Weight Loss costs $250 to $1,300 per month all-inclusive (medication + provider + supplies) nationally, with a median of $425 in ProcedureFinder's cash-pay benchmarks. Weekly dual GIP/GLP-1 agonist injection delivering 18 to 22 percent body weight loss in 72 weeks, slightly outperforming semaglutide in head-to-head trials.